2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-B0495A
    Lamotrigine hydrate 375347-20-9 98%
    Lamotrigine hydrate is a potent and orally active anticonvulsant or antiepileptic agent. Lamotrigine hydrate selectively blocks voltage-gated Na+ channels, stabilizing presynaptic neuronal membranes and inhibiting glutamate release. Lamotrigine hydrate can be used for the research of epilepsy, focal seizure, et al.
    Lamotrigine hydrate
  • HY-B0532B
    Trifluoperazine dimaleate 605-75-4 98%
    Trifluoperazine dimaleate, an antipsychotic agent, acts by blocking central dopamine receptors. Trifluoperazine dimaleate is a potent α1-adrenergic receptor antagonist. Trifluoperazine dimaleate is a potent NUPR1 inhibitor exerting anticancer activity. Trifluoperazine dimaleate is a calmodulin inhibitor, and also inhibits P-glycoprotein. Trifluoperazine dimaleate can be used for the research of schizophrenia. Trifluoperazine dimaleate acts as a reversible inhibitor of influenza virus morphogenesis.
    Trifluoperazine dimaleate
  • HY-B0590E
    Tetrabenazine mesylate 804-53-5 98%
    Tetrabenazine (Ro 1-9569) mesylate is a reversible inhibitor of the vesicular monoamine transporter VMAT2 with the Kd value of 1.34 nM. Tetrabenazine mesylate can be used for research on diseases related to hyperactive movement disorders such as Huntington's disease.
    Tetrabenazine mesylate
  • HY-B0725A
    Doxepin 1668-19-5 98%
    Doxepin inhibits reuptake of serotonin and norepinephrine as a tricyclic antidepressant. Doxepin has therapeutic effects in atopic dermatitis，chronic urticarial，can improve cognitive processes， protect central nervous system. Doxepin has also been proposed as a protective factor against oxidative stress.
    Doxepin
  • HY-B1057S
    Nefopam-d3 hydrochloride 1346603-30-2 ≥98.0%
    Nefopam-d3 (hydrochloride) is the deuterium labeled Nefopam hydrochloride. Nefopam hydrochloride (Fenazoxine hydrochloride) is a centrally-acting but non-opioid analgesic drug, for the relief of moderate to severe pain. Nefopam hydrochloride targets β-catenin protein level in mesenchymal cells in-vitro and in-vivo.
    Nefopam-d3 hydrochloride
  • HY-B1059S
    Levosulpiride-d3 124020-27-5 99.79%
    Levosulpiride-d3 is the deuterium labeled Levosulpiride. Levosulpiride (RV-12309) is the (S)-enantiomer of sulpiride, which is a D2 receptor a antagonist, an atypical antipsychotic agent of the benzamide class.
    Levosulpiride-d3
  • HY-B1232A
    Metyrapone Tartrate 908-35-0 98%
    Metyrapone (Su-4885) Tartrate is a potent and orally active 11β-hydroxylase inhibitor and an autophagy activator, also inhibits the production of aldosterone. Metyrapone Tartrate inhibits synthesis of endogenous adrenal corticosteroid, decreases glucocorticoid levels, and also affects behavior and emotion. In addition, Metyrapone Tartrate increases the efficiency of autophagic process via downregulation of mTOR pathway, and interacts with Pseudomonas putida cytochrome P-450. Metyrapone Tartrate can be used for researching Cushing's syndrome and depression.
    Metyrapone Tartrate
  • HY-B1395A
    Mecamylamine 60-40-2
    Mecamylamine is an orally active, nonselective, noncompetitive nAChR antagonist. Mecamylamine is also a ganglionic blocker. Mecamylamine can across the blood-brain barrier. Mecamylamine can be used in the research of neuropsychiatric disorders, hypertension, antidepressant area.
    Mecamylamine
  • HY-N0304A
    L-DOPA sodium 63302-01-2 98%
    L-DOPA (Levodopa) sodium is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA sodium can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA sodium has anti-allodynic effects, and can be used for Parkinson's disease research.
    L-DOPA sodium
  • HY-N2309A
    Kainic acid hydrate 58002-62-3 98%
    Kainic acid hydrate is a potent excitotoxic agent. Kainic acid hydrate also is an agonist for a subtype of ionotropic glutamate receptor. Kainic acid hydrate induces seizures.
    Kainic acid hydrate
  • HY-P99213
    Ozanezumab 1310680-64-8
    Ozanezumab (GSK1223249) is an anti-Nogo-A (neurite outgrowth inhibitor A) monoclonal antibody. Ozanezumab can be used in amyotrophic lateral sclerosis (ALS) and multiple sclerosis research.
    Ozanezumab
  • HY-P99886
    Pexelizumab 219685-93-5
    Pexelizumab (h5G1. 1-SC) is a humanized scFv monoclonal antibody directed against the C5 complement component. Pexelizumab inhibits apoptosis and leukocyte infiltration. Pexelizumab can be used for the research of cerebral IR injury and myocardial infarction.
    Pexelizumab
  • HY-100788C
    2-PMPA sodium 373645-42-2 98%
    2-PMPA sodium is a potent and selective inhibitor of glutamate carboxypeptidase II (GCPII) with an IC50 of 300 pM.
    2-PMPA sodium
  • HY-103107A
    LY334370 hydrochloride 199673-74-0 98%
    LY334370 hydrochloride is a selective 5-HT1F receptor agonist with a Kd value of 0.446 nM. LY334370 hydrochlorid has anti-migraine activity.
    LY334370 hydrochloride
  • HY-103234B
    GYKI 52466 hydrochloride 192065-56-8 98%
    GYKI 52466 hydrochloride is an orally active, highly selective and noncompetitive AMPA/kainate receptor antagonist with the IC50 values of 7.5 and 11μM, respectively. GYKI 52466 hydrochloride has good blood brain barrier permeability and anticonvulsant effect. GYKI 52466 hydrochloride can be used in Parkinson's disease research.
    GYKI 52466 hydrochloride
  • HY-103309A
    ML218 hydrochloride 2319922-08-0 98%
    ML218 hydrochloride is a potent, selective and orally active T-type Ca2+ channels (Cav3.1, Cav3.2, Cav3.3) inhibitor with IC50s of 310 nM and 270 nM for Cav3.2 and Cav3.3, respectively. ML218 hydrochloride inhibits the burst activity in subthalamic nucleus (STN) neurons. ML218 hydrochloride has no significant inhibition of L- or N-type calcium channels, KATP or hERG potassium channels. ML218 hydrochloride can penetrate the blood-brain barrier.
    ML218 hydrochloride
  • HY-104003A
    S 38093 hydrochloride 1222097-72-4 98%
    S 38093 hydrochloride is a brain-penetrant, orally active antagonist of H3 receptor, with Kis of 8.8, 1.44 and 1.2 µM for rat, mouse and human H3 receptors, respectively.
    S 38093 hydrochloride
  • HY-105008R
    Secoisolariciresinol diglucoside (Standard) 257930-74-8
    Secoisolariciresinol diglucoside (Standard) is the analytical standard of Secoisolariciresinol diglucoside. This product is intended for research and analytical applications. Secoisolariciresinol diglucoside ((S,S)-SDG), the main lignan in wholegrain flaxseed, is known for its beneficial effects including anti-inflammatory, antioxidant, anti-mutagenic, anti-microbial, anti-obesity, hypolipidemic, and neuroprotective effects[1][2].
    Secoisolariciresinol diglucoside (Standard)
  • HY-105670A
    PHA-543613 hydrochloride 1586767-92-1 98%
    PHA-543613 hydrochloride is an oral or active α7 nAChR agonist with brain permeability, For α3β4, α1β1γδ, α4β2 and 5-HT3 receptors selective. PHA-543613 hydrochloride affects sensory gating and memory in an in vivo model of schizophrenia.
    PHA-543613 hydrochloride
  • HY-105670B
    PHA-543613 dihydrochloride 478148-58-2 ≥99.0%
    PHA-543613 dihydrochloride is a potent, orally active, brain-penetrant and selective α7 nAChR agonist with a Ki value of 8.8 nM. PHA-543613 dihydrochloride displays selectivity for α7-nAChR over α3β4, α1β1γδ, α4β2 and 5-HT3 receptors. PHA-543613 dihydrochloride can be used for the cognitive deficits of Alzheimer's disease and schizophrenia research.
    PHA-543613 dihydrochloride
Cat. No. Product Name / Synonyms Application Reactivity